237 related articles for article (PubMed ID: 30092268)
1. Regenerating islet-derived 1α (REG-1α) protein increases tau phosphorylation in cell and animal models of tauopathies.
Moussaed M; Huc-Brandt S; Cubedo N; Silhol M; Murat S; Lebart MC; Kovacs G; Verdier JM; Trousse F; Rossel M; Marcilhac A
Neurobiol Dis; 2018 Nov; 119():136-148. PubMed ID: 30092268
[TBL] [Abstract][Full Text] [Related]
2. Regenerating islet-derived 1α (Reg-1α) protein is new neuronal secreted factor that stimulates neurite outgrowth via exostosin Tumor-like 3 (EXTL3) receptor.
Acquatella-Tran Van Ba I; Marchal S; François F; Silhol M; Lleres C; Michel B; Benyamin Y; Verdier JM; Trousse F; Marcilhac A
J Biol Chem; 2012 Feb; 287(7):4726-39. PubMed ID: 22158612
[TBL] [Abstract][Full Text] [Related]
3. Secernin-1 is a novel phosphorylated tau binding protein that accumulates in Alzheimer's disease and not in other tauopathies.
Pires G; McElligott S; Drusinsky S; Halliday G; Potier MC; Wisniewski T; Drummond E
Acta Neuropathol Commun; 2019 Dec; 7(1):195. PubMed ID: 31796108
[TBL] [Abstract][Full Text] [Related]
4. Human TAU
Cosacak MI; Bhattarai P; Bocova L; Dzewas T; Mashkaryan V; Papadimitriou C; Brandt K; Hollak H; Antos CL; Kizil C
Sci Rep; 2017 Oct; 7(1):12959. PubMed ID: 29021554
[TBL] [Abstract][Full Text] [Related]
5. Glycogen synthase kinase-3 is associated with neuronal and glial hyperphosphorylated tau deposits in Alzheimer's disease, Pick's disease, progressive supranuclear palsy and corticobasal degeneration.
Ferrer I; Barrachina M; Puig B
Acta Neuropathol; 2002 Dec; 104(6):583-91. PubMed ID: 12410379
[TBL] [Abstract][Full Text] [Related]
6. A new TAO kinase inhibitor reduces tau phosphorylation at sites associated with neurodegeneration in human tauopathies.
Giacomini C; Koo CY; Yankova N; Tavares IA; Wray S; Noble W; Hanger DP; Morris JDH
Acta Neuropathol Commun; 2018 May; 6(1):37. PubMed ID: 29730992
[TBL] [Abstract][Full Text] [Related]
7. HS3ST2 expression is critical for the abnormal phosphorylation of tau in Alzheimer's disease-related tau pathology.
Sepulveda-Diaz JE; Alavi Naini SM; Huynh MB; Ouidja MO; Yanicostas C; Chantepie S; Villares J; Lamari F; Jospin E; van Kuppevelt TH; Mensah-Nyagan AG; Raisman-Vozari R; Soussi-Yanicostas N; Papy-Garcia D
Brain; 2015 May; 138(Pt 5):1339-54. PubMed ID: 25842390
[TBL] [Abstract][Full Text] [Related]
8. Improved long-term potentiation and memory in young tau-P301L transgenic mice before onset of hyperphosphorylation and tauopathy.
Boekhoorn K; Terwel D; Biemans B; Borghgraef P; Wiegert O; Ramakers GJ; de Vos K; Krugers H; Tomiyama T; Mori H; Joels M; van Leuven F; Lucassen PJ
J Neurosci; 2006 Mar; 26(13):3514-23. PubMed ID: 16571759
[TBL] [Abstract][Full Text] [Related]
9. Phosphorylated mitogen-activated protein kinase (MAPK/ERK-P), protein kinase of 38 kDa (p38-P), stress-activated protein kinase (SAPK/JNK-P), and calcium/calmodulin-dependent kinase II (CaM kinase II) are differentially expressed in tau deposits in neurons and glial cells in tauopathies.
Ferrer I; Blanco R; Carmona M; Puig B
J Neural Transm (Vienna); 2001; 108(12):1397-415. PubMed ID: 11810404
[TBL] [Abstract][Full Text] [Related]
10. Combining P301L and S320F tau variants produces a novel accelerated model of tauopathy.
Koller EJ; Gonzalez De La Cruz E; Machula T; Ibanez KR; Lin WL; Williams T; Riffe CJ; Ryu D; Strang KH; Liu X; Janus C; Golde TE; Dickson D; Giasson BI; Chakrabarty P
Hum Mol Genet; 2019 Oct; 28(19):3255-3269. PubMed ID: 31261380
[TBL] [Abstract][Full Text] [Related]
11. Ultrastructural neuronal pathology in transgenic mice expressing mutant (P301L) human tau.
Lin WL; Lewis J; Yen SH; Hutton M; Dickson DW
J Neurocytol; 2003 Nov; 32(9):1091-105. PubMed ID: 15044841
[TBL] [Abstract][Full Text] [Related]
12. Tau Protein and Zebrafish Models for Tau-Induced Neurodegeneration.
Ding Y; Lei L; Lai C; Tang Z
J Alzheimers Dis; 2019; 69(2):339-353. PubMed ID: 31006683
[TBL] [Abstract][Full Text] [Related]
13. Pazopanib Reduces Phosphorylated Tau Levels and Alters Astrocytes in a Mouse Model of Tauopathy.
Javidnia M; Hebron ML; Xin Y; Kinney NG; Moussa CE
J Alzheimers Dis; 2017; 60(2):461-481. PubMed ID: 28869476
[TBL] [Abstract][Full Text] [Related]
14. Truncated tau expression levels determine life span of a rat model of tauopathy without causing neuronal loss or correlating with terminal neurofibrillary tangle load.
Koson P; Zilka N; Kovac A; Kovacech B; Korenova M; Filipcik P; Novak M
Eur J Neurosci; 2008 Jul; 28(2):239-46. PubMed ID: 18702695
[TBL] [Abstract][Full Text] [Related]
15. Raphé tauopathy alters serotonin metabolism and breathing activity in terminal Tau.P301L mice: possible implications for tauopathies and Alzheimer's disease.
Menuet C; Borghgraef P; Matarazzo V; Gielis L; Lajard AM; Voituron N; Gestreau C; Dutschmann M; Van Leuven F; Hilaire G
Respir Physiol Neurobiol; 2011 Sep; 178(2):290-303. PubMed ID: 21763469
[TBL] [Abstract][Full Text] [Related]
16. Age-dependent neurofibrillary tangle formation, neuron loss, and memory impairment in a mouse model of human tauopathy (P301L).
Ramsden M; Kotilinek L; Forster C; Paulson J; McGowan E; SantaCruz K; Guimaraes A; Yue M; Lewis J; Carlson G; Hutton M; Ashe KH
J Neurosci; 2005 Nov; 25(46):10637-47. PubMed ID: 16291936
[TBL] [Abstract][Full Text] [Related]
17. Phosphorylation and oligomerization of α-synuclein associated with GSK-3β activation in the rTg4510 mouse model of tauopathy.
Takaichi Y; Chambers JK; Inoue H; Ano Y; Takashima A; Nakayama H; Uchida K
Acta Neuropathol Commun; 2020 Jun; 8(1):86. PubMed ID: 32560668
[TBL] [Abstract][Full Text] [Related]
18. Changed conformation of mutant Tau-P301L underlies the moribund tauopathy, absent in progressive, nonlethal axonopathy of Tau-4R/2N transgenic mice.
Terwel D; Lasrado R; Snauwaert J; Vandeweert E; Van Haesendonck C; Borghgraef P; Van Leuven F
J Biol Chem; 2005 Feb; 280(5):3963-73. PubMed ID: 15509565
[TBL] [Abstract][Full Text] [Related]
19. Threonine
Moszczynski AJ; Yang W; Hammond R; Ang LC; Strong MJ
Acta Neuropathol Commun; 2017 Jan; 5(1):6. PubMed ID: 28077166
[TBL] [Abstract][Full Text] [Related]
20. Maturation of neuronal AD-tau pathology involves site-specific phosphorylation of cytoplasmic and synaptic tau preceding conformational change and fibril formation.
Aragão Gomes L; Uytterhoeven V; Lopez-Sanmartin D; Tomé SO; Tousseyn T; Vandenberghe R; Vandenbulcke M; von Arnim CAF; Verstreken P; Thal DR
Acta Neuropathol; 2021 Feb; 141(2):173-192. PubMed ID: 33427938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
